Compare Stocks: GERN, ALKS, DNLI, and AMLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$39.66 +1.5%	$45.34	$27.00 ▼ $55.67	$6.66B	0.32	2.14 million shs	1.15 million shs
AMLX Amylyx Pharmaceuticals	$27.79 +2.8%	$30.77	$10.83 ▼ $41.14	$3.10B	-0.1	1.65 million shs	407,429 shs
DNLI Denali Therapeutics	$18.39 +2.9%	$22.07	$13.75 ▼ $27.30	$2.94B	1.02	1.73 million shs	711,245 shs
GERN Geron	$1.23 +2.9%	$1.39	$1.04 ▼ $2.01	$787.03M	0.61	13.71 million shs	2.38 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-1.64%	-5.69%	-14.73%	-24.76%	+22.35%
AMLX Amylyx Pharmaceuticals	+0.67%	-1.46%	-19.65%	+58.81%	+90.49%
DNLI Denali Therapeutics	-2.88%	-6.73%	-15.79%	-21.38%	+17.49%
GERN Geron	-0.83%	-0.83%	-13.14%	-16.20%	-4.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$39.66 +1.5%	$45.34	$27.00 ▼ $55.67	$6.66B	0.32	2.14 million shs	1.15 million shs
AMLX Amylyx Pharmaceuticals	$27.79 +2.8%	$30.77	$10.83 ▼ $41.14	$3.10B	-0.1	1.65 million shs	407,429 shs
DNLI Denali Therapeutics	$18.39 +2.9%	$22.07	$13.75 ▼ $27.30	$2.94B	1.02	1.73 million shs	711,245 shs
GERN Geron	$1.23 +2.9%	$1.39	$1.04 ▼ $2.01	$787.03M	0.61	13.71 million shs	2.38 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-1.64%	-5.69%	-14.73%	-24.76%	+22.35%
AMLX Amylyx Pharmaceuticals	+0.67%	-1.46%	-19.65%	+58.81%	+90.49%
DNLI Denali Therapeutics	-2.88%	-6.73%	-15.79%	-21.38%	+17.49%
GERN Geron	-0.83%	-0.83%	-13.14%	-16.20%	-4.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.74	Moderate Buy	$54.47	37.35% Upside
AMLX Amylyx Pharmaceuticals	3.00	Buy	$40.71	46.52% Upside
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.85	94.89% Upside
GERN Geron	2.20	Hold	$4.00	226.53% Upside

Current Analyst Ratings Breakdown

Latest GERN, ALKS, DNLI, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$32.00 ➝ $39.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$50.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold	$50.00
9/22/2026	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$56.00
9/22/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$58.00 ➝ $61.00
9/21/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
9/21/2026	ALKS Alkermes	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/21/2026	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$62.00
9/16/2026	ALKS Alkermes	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$55.00 ➝ $57.00
8/25/2026	DNLI Denali Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$30.00 ➝ $35.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	4.51	$1.67 per share	23.73	$11.02 per share	3.60
AMLX Amylyx Pharmaceuticals	$87.37M	35.44	N/A	N/A	$2.78 per share	10.00
DNLI Denali Therapeutics	$3.60M	815.78	N/A	N/A	$6.91 per share	2.66
GERN Geron	$183.88M	4.28	N/A	N/A	$0.35 per share	3.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	104.44	165.24	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	20.42	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)

Latest GERN, ALKS, DNLI, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AMLX Amylyx Pharmaceuticals	-$0.3831	N/A	N/A	N/A	$0.06 million	N/A
11/5/2026	Q3 2026	DNLI Denali Therapeutics	-$0.3707	N/A	N/A	N/A	$12.22 million	N/A
11/4/2026	Q3 2026	GERN Geron	-$0.01	N/A	N/A	N/A	$60.70 million	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0788	N/A	N/A	N/A	$463.35 million	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
DNLI Denali Therapeutics	0.01	8.37	8.32
GERN Geron	0.55	6.91	5.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
AMLX Amylyx Pharmaceuticals	95.84%
DNLI Denali Therapeutics	92.92%
GERN Geron	73.71%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
AMLX Amylyx Pharmaceuticals	10.90%
DNLI Denali Therapeutics	9.70%
GERN Geron	1.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
DNLI Denali Therapeutics	507	159.85 million	144.34 million	Optionable
GERN Geron	258	642.47 million	631.49 million	Optionable

GERN, ALKS, DNLI, and AMLX Headlines

Recent News About These Companies

Geron Corporation (GERN) Analyst Insights, Price Targets & Recommendations - Yahoo Finance

October 15 at 8:30 AM | finance.yahoo.com

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

October 13 at 2:52 PM | prnewswire.com

Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

October 12 at 9:00 AM | globenewswire.com

Geron reports 17 percent revenue growth: Geron stock has a USD 4.25 target

October 8, 2026 | ad-hoc-news.deA

Bank of America Corp DE Purchases New Stake in Geron Corporation $GERN

September 29, 2026 | marketbeat.com

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

September 25, 2026 | prnewswire.com

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

September 25, 2026 | prnewswire.com

【GERN】Geron

September 23, 2026 | note.comN

Geron stock trades at USD 1.30 as market cap reaches USD 835.2 million

September 22, 2026 | ad-hoc-news.deA

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 18, 2026 | globenewswire.com

Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

September 16, 2026 | marketbeat.com

Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

September 14, 2026 | businesswire.com

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

September 2, 2026 | prnewswire.com

Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm

September 2, 2026 | prnewswire.com

Geron to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2026 | globenewswire.com

Geron Corp.: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis

August 18, 2026 | seekingalpha.com

Geron’s RYTELO Drives Revenue as Trial Risks Linger

August 16, 2026 | tipranks.com

Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed?

August 9, 2026 | finance.yahoo.com

Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative

August 9, 2026 | finance.yahoo.com

Geron Corporation Stock (GERN) Opinions on Recent Price Surge and Trial Updates

August 8, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GERN, ALKS, DNLI, and AMLX Company Descriptions

Alkermes NASDAQ:ALKS

$39.66 +0.58 (+1.48%)

As of 02:08 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Amylyx Pharmaceuticals NASDAQ:AMLX

$27.79 +0.76 (+2.80%)

As of 02:08 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Denali Therapeutics NASDAQ:DNLI

$18.39 +0.52 (+2.93%)

As of 02:08 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Geron NASDAQ:GERN

$1.23 +0.04 (+2.94%)

As of 02:08 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, ALKS, DNLI, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, ALKS, DNLI, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, ALKS, DNLI, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, ALKS, DNLI, and AMLX Company Descriptions

Alkermes NASDAQ:ALKS

Amylyx Pharmaceuticals NASDAQ:AMLX

Denali Therapeutics NASDAQ:DNLI

Geron NASDAQ:GERN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, ALKS, DNLI, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, ALKS, DNLI, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, ALKS, DNLI, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, ALKS, DNLI, and AMLX Company Descriptions

Alkermes NASDAQ:ALKS

Amylyx Pharmaceuticals NASDAQ:AMLX

Denali Therapeutics NASDAQ:DNLI

Geron NASDAQ:GERN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools